Submucosa

Micro-Tech Endoscopy Announces the Release of its New Submucosal Lifting Agent

Retrieved on: 
Tuesday, June 22, 2021
Branches of biology, Digestive system, Clinical medicine, Medicine, Membrane biology, Submucosa, Gastrointestinal cancer, Gastrointestinal tract, ESD, Endoscopic submucosal dissection

ANN ARBOR, Mich., June 22, 2021 /PRNewswire/ -- Micro-Tech Endoscopy recently expanded its EMR and ESD portfolio with the launch of its BlueBoost submucosal lift.

Key Points: 
  • ANN ARBOR, Mich., June 22, 2021 /PRNewswire/ -- Micro-Tech Endoscopy recently expanded its EMR and ESD portfolio with the launch of its BlueBoost submucosal lift.
  • BlueBoost is a viscous submucosal injection fluid designed to increase the efficiency of resection procedures.
  • Lifts and separates the gastrointestinal mucosa from the submucosal layer to help identify the margin around the lesion.
  • Micro-Tech Endoscopy has operations in America, Asia, and Europe and leverages this global reach to refine the products the company provides to partners.

Aziyo Biologics Announces Product Design Completion for its Next Generation CanGaroo® Envelope for Implantable Electronic Devices

Retrieved on: 
Thursday, February 11, 2021
Branches of biology, Prosthetics, Biomedical engineering, Tissue engineering, Implant, Submucosa, Biology, Extracellular matrix, Medicine

CanGaroo is the only commercially available biological envelope that forms a natural, systematically vascularized pocket for holding implantable electronic devices.

Key Points: 
  • CanGaroo is the only commercially available biological envelope that forms a natural, systematically vascularized pocket for holding implantable electronic devices.
  • We are delighted to reach this important milestone in the advancement of our CanGaroo platform, said Ron Lloyd, President and Chief Executive Officer of Aziyo.
  • In addition to evidencing an inherent ability to establish healthy tissue and secure implantable electronic devices in place, incorporating antibiotics with our biological envelope has the potential to reduce the risk of infection in patients receiving these devices.
  • The CanGaroo Envelope is a small intestine submucosa extracellular matrix designed to mitigate complications deriving from implantable electronic devices and the shortcomings of synthetic envelopes.

Global Gastric Cancer Forecast and Market Analysis to 2027: No Targeted Therapies Exist for Locoregional Disease, Although Opdivo and Keytruda are in Ongoing Phase III Trials for this Setting - ResearchAndMarkets.com

Retrieved on: 
Friday, January 29, 2021
General Health, Pharmaceutical, Health, Oncology, Branches of biology, Abdomen, Digestive system, Clinical medicine, Membrane biology, Cancer treatments, Organs, Stomach cancer, Muscularis mucosae, Stomach, Muscularis, Submucosa

Stomach or gastric cancer (GC) refers to any cancer arising in the lining of the stomach.

Key Points: 
  • Stomach or gastric cancer (GC) refers to any cancer arising in the lining of the stomach.
  • In most cases, gastric adenocarcinomas will begin in the muscularis mucosae and submucosa, then invading deeper lamina of the gastric wall.
  • The majority of gastric cancer diagnoses (66.1%) worldwide are in males, ranging from 54.3% to 68.3% across regions.
  • No targeted therapies exist for locoregional disease, although Opdivo and Keytruda are in ongoing Phase III trials for this setting.

GI Supply Gets FDA Clearance of First Submucosal Lifting Agent in a Pre-filled 5mL Syringe

Retrieved on: 
Tuesday, July 14, 2020
Branches of biology, Digestive system, Membrane biology, Submucosa, Diagnostic gastroenterology, Injection, Endoscopy, Absorption, Biology

The pre-filled syringe eliminates the time and expense associated with mixing and preparing the agent.

Key Points: 
  • The pre-filled syringe eliminates the time and expense associated with mixing and preparing the agent.
  • This results in a lifting agent that is specially formulated with water-retaining properties, which causes a slower rate of absorption because of osmotic resistance.
  • "GI Supply has been an expert in the field of submucosal injection agents for 20 years with our Spot and SpotEx endoscopic tattoos.
  • GI Supply is broadening our portfolio with solutions that allow physicians to perform more-advanced procedures safely, efficiently and economically.

EndoClot Plus, Inc. Announces FDA Clearance of GI Submucosal Lifting Product

Retrieved on: 
Wednesday, February 19, 2020
FDA, Surgery, Medical devices, Health, Oncology, Medical specialties, Medicine, Branches of biology, Digestive system, Diagnostic gastroenterology, Membrane biology, Submucosa, Polyp, Endoscopy, Gastrointestinal tract, Adenoma, Endoscopic submucosal dissection

(EPI), a privately held medical device company announced the FDA 510(k) clearance of EndoClot Submucosal Injection Agent (EndoClot SIA) manufactured by EndoClot Plus Co., Ltd. located in Suzhou, China.

Key Points: 
  • (EPI), a privately held medical device company announced the FDA 510(k) clearance of EndoClot Submucosal Injection Agent (EndoClot SIA) manufactured by EndoClot Plus Co., Ltd. located in Suzhou, China.
  • EndoClot SIA is the first starch-derived submucosal injection system cleared in the U.S. market for endoscopic removal of polyps, adenomas, early stage cancers and other gastrointestinal mucosal lesions.
  • EndoClot Plus is focused on utilizing its polymer expertise to develop customized medical devices to meet GI clinical needs.
  • With its innovative technology platforms EndoClot Plus aims to become the leading company in creating new biomaterial therapeutic solutions for GI Endoscopy.

Lumendi Receives 510(k) Clearance for DiLumen Ik™ Endolumenal Interventional Knife

Retrieved on: 
Tuesday, August 20, 2019
General Health, Medical devices, Health, Medical Supplies, Medicine, Branches of biology, Clinical medicine, Diagnostic gastroenterology, Digestive system, Membrane biology, Submucosa, Surgery, Endoscopy

Connecticut-based medical device innovator Lumendi, LLC ( http://www.lumendi.com ) has announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the DiLumen Ik Endolumenal Interventional Knife, a sterile, single-use, disposable monopolar electrosurgical device for cutting, dissecting, and cauterizing tissue within the digestive tract during endoscopic procedures.

Key Points: 
  • Connecticut-based medical device innovator Lumendi, LLC ( http://www.lumendi.com ) has announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the DiLumen Ik Endolumenal Interventional Knife, a sterile, single-use, disposable monopolar electrosurgical device for cutting, dissecting, and cauterizing tissue within the digestive tract during endoscopic procedures.
  • The DiLumen Ik is also designed to deliver a seamless submucosal injection to create and maintain a fluid cushion during tissue dissection.
  • This is the seventh device Lumendi has developed as the company continues to advance minimally invasive endolumenal therapies.
  • Ig Endolumenal Interventional Grasper, a flexible endoscopic tool intended to grasp and manipulate tissue within the digestive tract under direct endoscopic visualization.

Lumendi Brands Exclusive Tissue Manipulation Feature for Company’s DiLumen EIP

Retrieved on: 
Tuesday, June 11, 2019
Surgery, Health, Biotechnology, Hospitals, Medical devices, General Health, Medicine, Medical specialties, Clinical medicine, Digestive system, Membrane biology, Submucosa, Polyp, Endoscopy, Endoscopic submucosal dissection

View the full release here: https://www.businesswire.com/news/home/20190611005268/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190611005268/en/
    The DiLumen +DR is a new feature of the fore balloon assembly to help facilitate tissue manipulation for easier dissection and resection of polyps without the need for surgical intervention.
  • TheDiLumen +DR consistently provideseffective tissue retraction, continuous tissue tension, and superior visualization of submucosal tissue planes enabling precise dissection.
  • According to Dr. Peter Johann, CEO of Lumendi, Ltd., This modification to DiLumen has the potential to revolutionize tissue manipulation during both ESD and EMR.
  • Lumendi Ltd. holds a worldwide exclusive license from Cornell University on the DiLumen technology.